We are live on ! Find out more
CRBU icon

Caribou Biosciences

140 hedge funds and large institutions have $87.6M invested in Caribou Biosciences in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 43

7% less funds holding

Funds holding: 151140 (-11)

15.05% less ownership

Funds ownership: 73.91%58.86% (-15%)

25% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 36

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less call options, than puts

Call options by funds: $54K | Put options by funds: $163K

74% less capital invested

Capital invested by funds: $343M → $87.6M (-$255M)

Holders
140
Holders Change
-11
Holders Change %
-7.28%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
27
Increased
41
Reduced
43
Closed
36
Calls
$54K
Puts
$163K
Net Calls
-$109K
Net Calls Change
-$182K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$11.4M -$183K -57,242 -0.8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.45M +$1.39M +433,911 +11%
Bank of America
3
Bank of America
North Carolina
$6.83M +$9.73M +3,045,578 +273%
PHS
4
PFM Health Sciences
California
$6.7M -$7.67M -2,399,898 -37%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$4.3M +$1.71M +536,162 +26%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$3.84M -$3.97M -1,241,478 -35%
EWM
7
Elmwood Wealth Management
California
$3.83M -$94.3K -29,500 -1%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$3.13M +$203K +63,478 +3%
KCM
9
Kynam Capital Management
New Jersey
$2.7M +$1.85M +578,175 +54%
State Street
10
State Street
Massachusetts
$2.65M -$15.1M -4,731,742 -75%
Renaissance Technologies
11
Renaissance Technologies
New York
$2.43M +$4.74M +1,482,900 New
Fidelity Investments
12
Fidelity Investments
Massachusetts
$2.41M +$85.4K +26,725 +2%
Goldman Sachs
13
Goldman Sachs
New York
$1.95M +$1.87M +585,862 +97%
Two Sigma Investments
14
Two Sigma Investments
New York
$1.84M +$2.84M +889,438 +387%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$1.7M +$3.16M +989,300 +2,132%
SSA
16
Schonfeld Strategic Advisors
New York
$1.46M -$3.04M -951,058 -52%
Fidelity International
17
Fidelity International
Bermuda
$1.41M
RCMU
18
Rokos Capital Management (UK)
United Kingdom
$1.37M
Millennium Management
19
Millennium Management
New York
$1.18M +$1.91M +599,033 +493%
Northern Trust
20
Northern Trust
Illinois
$1.16M -$77.1K -24,136 -3%
Jane Street
21
Jane Street
New York
$1.1M +$1.94M +607,281 +992%
MC
22
Maverick Capital
Texas
$1.07M
CS
23
Candriam SCA
Luxembourg
$1.03M -$1.66M -520,000 -45%
Charles Schwab
24
Charles Schwab
California
$1.02M -$650K -203,452 -25%
Morgan Stanley
25
Morgan Stanley
New York
$1.01M +$652K +203,990 +49%

CRBU Hedge Fund Activity: Q2 2024 in Review

140 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2024, worth a combined $87.6M — down 74% from $343M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBU and 27 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 41 added.

The largest buyer was Bank of America, adding an estimated $9.73M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.7M sold.

  • 140 institutional investors held Caribou Biosciences (CRBU) as of Q2 2024, down from 151 in Q1 2024.
  • Funds reported $87.6M of Caribou Biosciences stock for Q2 2024, down 74% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q2 2024 and 36 closed out, a net change of -9 holders.
  • The largest Caribou Biosciences buyer in Q2 2024 was Bank of America, an estimated $9.73M added.
  • The largest Caribou Biosciences seller in Q2 2024 was Avidity Partners Management, an estimated $29.7M sold.

Based on aggregated 13F filings for Q2 2024.